title: How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?
abstract: In the last 15 years the management of inflammatory bowel disease has evolved greatly, largely through the increased use of immunomodulators and, especially, anti-tumor necrosis factor (anti-TNF) biologic agents. Within this time period, confidence in the use of anti-TNFs has increased, whilst, especially in recent years, the efficacy and safety of thiopurines has been questioned. Yet despite recent concerns regarding the risk: benefit profile of thiopurines, combination therapy with an immunomodulator and an anti-TNF has emerged as the recommended treatment strategy for the majority of patients with moderate-severe disease, especially those who are recently diagnosed. Concurrently, therapeutic drug monitoring has emerged as a means of optimizing the dosage of both immunomodulators and anti-TNFs. However the recommended therapeutic target levels for both drug classes were largely derived from studies of monotherapy with either agent, or studies underpowered to analyze outcomes in combination therapy patients. It has been assumed that these target levels are applicable to patients on combination therapy also, however there are few data to support this. Similarly, the timing and duration of treatment with immunomodulators when used in combination therapy remains unknown. Recent attention, including post hoc analyses of the pivotal registration trials, has focused on the optimization of anti-TNF agents, when used as either monotherapy or combination therapy. This review will instead focus on how best to optimize immunomodulators when used in combination therapy, including an evaluation of recent data addressing unanswered questions regarding the optimal timing, dosage and duration of immunomodulator therapy in combination therapy patients.
authors.affiliation: Mark G Ward, Miles P Sparrow, Department of Gastroenterology, The Alfred Hospital, Melbourne 3004, Australia.
authors.forename: Mark G
authors.initials: MG
authors.lastname: Ward
authors.affiliation: Mark G Ward, Miles P Sparrow, Department of Gastroenterology, The Alfred Hospital, Melbourne 3004, Australia.
authors.forename: Peter M
authors.initials: PM
authors.lastname: Irving
authors.affiliation: Mark G Ward, Miles P Sparrow, Department of Gastroenterology, The Alfred Hospital, Melbourne 3004, Australia.
authors.forename: Miles P
authors.initials: MP
authors.lastname: Sparrow
mesh_terms: D001688:Biological Products / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D018579:Patient Selection; D012074:Remission Induction; D012307:Risk Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
chemical_list: D001688:Biological Products; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha
keywords: Combination therapy; Drug monitoring; Inflammatory bowel disease; Thiopurines; Tumor necrosis factor-alpha